| 13.44 -0.01 (-0.07%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 15.75  |
1-year : | 18.4 |
| Resists | First : | 13.48 |
Second : | 15.75 |
| Pivot price | 13.39 |
|||
| Supports | First : | 13.34 |
Second : | 13.26 |
| MAs | MA(5) : | 13.41 |
MA(20) : | 13.39 |
| MA(100) : | 9.51 |
MA(250) : | 9.09 |
|
| MACD | MACD : | 0.3  |
Signal : | 0.5 |
| %K %D | K(14,3) : | 57 |
D(3) : | 47.2 |
| RSI | RSI(14): 73.6 |
|||
| 52-week | High : | 13.48 | Low : | 5.68 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ OGN ] has closed below upper band by 11.0%. Bollinger Bands are 95.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 13.51 - 13.58 | 13.58 - 13.63 |
| Low: | 13.27 - 13.34 | 13.34 - 13.4 |
| Close: | 13.33 - 13.45 | 13.45 - 13.54 |
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Mon, 15 Jun 2026
Organon (OGN) Stock After New TOFIDENCE Approval A Fresh Look At Valuation And Recovery Potential - Yahoo Finance
Sat, 13 Jun 2026
Organon (OGN) Stock Valuation After FDA Expands TOFIDENCE Approval In US Biosimilars Market - simplywall.st
Fri, 12 Jun 2026
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19 - Zacks Investment Research
Fri, 12 Jun 2026
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19 - Yahoo Finance
Wed, 10 Jun 2026
Organon wins US approval to widen use of arthritis biosimilar drug - Reuters
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 263 (M) |
| Shares Float | 261 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 77.7 (%) |
| Shares Short | 20,040 (K) |
| Shares Short P.Month | 18,610 (K) |
| EPS | 0.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.44 |
| Profit Margin | 3.9 % |
| Operating Margin | 18.7 % |
| Return on Assets (ttm) | 5.8 % |
| Return on Equity (ttm) | 34 % |
| Qtrly Rev. Growth | -3.5 % |
| Gross Profit (p.s.) | 12.64 |
| Sales Per Share | 23.45 |
| EBITDA (p.s.) | 6.09 |
| Qtrly Earnings Growth | 66.6 % |
| Operating Cash Flow | 850 (M) |
| Levered Free Cash Flow | 529 (M) |
| PE Ratio | 14.45 |
| PEG Ratio | 0 |
| Price to Book value | 3.9 |
| Price to Sales | 0.57 |
| Price to Cash Flow | 4.15 |
| Dividend | 0.01 |
| Forward Dividend | 0 |
| Dividend Yield | 0.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|